These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21952702)

  • 1. Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis.
    Piccoli Lde Z; Mattos AA; Coral GP; Mattos AZ; Santos DE
    Arq Gastroenterol; 2011; 48(3):179-85. PubMed ID: 21952702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
    Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
    Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
    Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
    Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
    J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.
    Fabris P; Floreani A; Carlotto A; Baldo V; Bozzola L; Giordani MT; Negro F; Rassu M; Tramarin A; de Lalla F
    Aliment Pharmacol Ther; 2005 May; 21(9):1173-8. PubMed ID: 15854181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.
    Thomopoulos KC; Theocharis GJ; Tsamantas AC; Siagris D; Dimitropoulou D; Gogos CA; Labropoulou-Karatza C
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):149-53. PubMed ID: 15674091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
    Romero-Gómez M; Del Mar Viloria M; Andrade RJ; Salmerón J; Diago M; Fernández-Rodríguez CM; Corpas R; Cruz M; Grande L; Vázquez L; Muñoz-De-Rueda P; López-Serrano P; Gila A; Gutiérrez ML; Pérez C; Ruiz-Extremera A; Suárez E; Castillo J
    Gastroenterology; 2005 Mar; 128(3):636-41. PubMed ID: 15765399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
    Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.
    Abbas Z; Moatter T; Hussainy A; Jafri W
    World J Gastroenterol; 2005 Nov; 11(42):6656-61. PubMed ID: 16425360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
    Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
    Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
    J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
    Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
    J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
    Petta S; Di Marco V; Di Stefano R; Cabibi D; Cammà C; Marchesini G; Craxì A
    J Viral Hepat; 2011 Jul; 18(7):e372-80. PubMed ID: 21692950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should active injecting drug users receive treatment for chronic hepatitis C?
    Papadopoulos V; Gogou A; Mylopoulou T; Mimidis K
    Arq Gastroenterol; 2010; 47(3):238-41. PubMed ID: 21140082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
    J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.
    Ponziani FR; Viganò R; Iemmolo RM; Donato MF; Rendina M; Toniutto P; Pasulo L; Morelli MC; Burra P; Miglioresi L; Merli M; Di Paolo D; Fagiuoli S; Gasbarrini A; Pompili M; ; Belli L; Gerunda GE; Marino M; Montalti R; Di Benedetto F; De Ruvo N; Rigamonti C; Colombo M; Rossi G; Di Leo A; Lupo L; Memeo V; Bringiotti R; Zappimbulso M; Bitetto D; Vero V; Colpani M; Fornasiere E; Pinna AD; Morelli MC; Bertuzzo V; De Martin E; Senzolo M; Ettorre GM; Visco-Comandini U; Antonucci G; Angelico M; Tisone G; Giannelli V; Giusto M
    Dig Liver Dis; 2014 May; 46(5):440-5. PubMed ID: 24635906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.